This competition year, in accordance with our work, the Judging Form, and iGEM’s judging rubric, we are eligible for the following awards and medals:
Our team successfully completed all Competition Deliverables required by the competition: Wiki, Judging Form, Presentation Video, and Judging Session.
Our team successfully completed the Attributions Form, which documents specific contributions of our Members (Student Leaders and Members), Supervisors (Principal Investigator, Instructors, and Student Advisors), and External Advisors/Contractors.
To make useful contribution for future iGEM teams, we made following changes to the Registry:
Besides the five new parts we added to the Registry, we added two additional parts to the Registry for engineering purposes. The additions are as follows:
*The pgxC signal peptide was modified by a silent PstI site removal to restore RFC 10 compatibility while maintaining the original amino acid sequence and secretion functionality.
Our team successfully demonstrated engineering success in a part of our project by going through at least one iteration of the engineering design cycle. Demonstrating how synthetic biology tools and experimental techniques can generate expected results to tackle and solve our project’s problem, we documented our engineering design cycle as a distinct Design → Build → Test → Learn phase. Our engineering cycle comprises our New Composite Part:
pTRKH3 with Engineered N-terminal Secretion Signal Peptide pgxC Composite Part (Final Construct; BBa_252WDOMF–later modified to as BBa_25TXYOA2)
Our team successfully determined that our work is good and responsible to the world by completing and documenting an exhaustive series of Human Practices work:
Our Human Practices work effectively shows how our project affects society–and how society influences the direction of our project. We effectively describe how ethical considerations and stakeholder input guided our project purpose, design, and experiments we conduct in the lab–in essence, how the feedback entered into the process of our work throughout the year.
Our Human Practices work features excellence by its (1) coherent integration throughout the project; (2) inspiration from and to other iGEM projects; (3) scalability and replicability by other iGEM teams supported by a strong and exhaustive documentation; (4) thoughtful implementation with references to the context, rationale, and prior work; and (5) effective incorporation of different stakeholder views throughout the project.
Through our Bradford Assay, SDS-PAGE Analysis, and DNS Assay, our well-reported measurements show that our design functions correctly and that our result is actually important. Our measurement work comprises identification of appropriate measurement targets, collection of precise measurements, and clear reporting of appropriate results.
Our Bradford Assay, SDS-PAGE Analysis, and DNS Assay feature excellence by their (1) replicability by other iGEM teams; (2) holistic nature of protocol description and documentation; (3) potential application to other iGEM projects; and (4) the use of appropriate controls to validate the measurement process and calibrate units.
This year, we are proud to showcase our New Composite Part to the iGEM community:
pTRKH3 with Engineered N-terminal Secretion Signal Peptide pgxC Composite Part (Final Construct; BBa_252WDOMF–later modified to as BBa_25TXYOA2)
*NOTE: BBa_25TXYOA2 is the final submission.
This New Composite Part is highly documented with a combination of genetic components and experimental details and data. We encourage judges to reference both BBa_25TXYOA2 and our Parts page. Our New Composite Part showcases excellence by its (1) experimental proof that the part can be well characterized and modeled and (2) usefulness to the community.
Our project well satisfies the General Project Criteria by accomplishing the following:
Our project well satisfies the Presentation Criteria by accomplishing the following:
Our project well satisfies the Wiki Criteria by accomplishing the following: